2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2175

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: L05

Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2177

Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2710

Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2124

Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2100

Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2589

Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2709

Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2272

Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies

Psychology/Social Science Poster – ARP

9:00AM-11:00AM: Abstract Number: 1982

Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2116

Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2496

Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2428

Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2198

Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2271

Sexual Health, Intimacy and Rheumatology Practices

Psychology/Social Science Poster – ARP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].